With the approval of ABRYSVO® for adults aged 18+, there is now a way to help protect against RSV in a population that previously did not have vaccination options. KIRKLAND, QC, Oct. 21, 2025 /CNW/ - ...

Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory ...

KIRKLAND, QC, Oct. 23, 2025 /CNW/ - Pfizer Canada is pleased to announce that ABRYSVO, its vaccine for the prevention of Respiratory Syncytial Virus (RSV), has been selected for public funding in ...

A study of nursing home residents demonstrated that vaccination against respiratory syncytial virus reduced their risk for ...

Pfizer Inc.’s vaccine to protect against a potentially dangerous respiratory infection will be offered to about three million ...

England’s National Health Service announced on Thursday that three million more older adults in the country will be eligible to receive Pfizer’s (PFE) respiratory syncytial virus (RSV) vaccine, ...

Credit: Getty Images. Abrysvo is expected to be available in the third quarter of 2023. The Food and Drug Administration (FDA) has approved Abrysvo ™ (respiratory syncytial virus vaccine) for the ...

The Japanese health ministry is set to begin regular vaccinations for respiratory syncytial virus, or RSV, which can cause pneumonia in infants, on Wednesday, the start of fiscal 2026. Infants in Japa ...